Literature DB >> 28973406

Targeting Accuracy of the Subthalamic Nucleus in Deep Brain Stimulation Surgery: Comparison Between 3 T T2-Weighted Magnetic Resonance Imaging and Microelectrode Recording Results.

Andreas Nowacki1, Ines Debove2, Michael Fiechter1, Frédéric Rossi1, Markus Florian Oertel1, Roland Wiest3, Michael Schüpbach2, Claudio Pollo1.   

Abstract

BACKGROUND: Targeting accuracy in deep brain stimulation (DBS) surgery can be defined as the level of accordance between selected and anatomic real target reflected by characteristic electrophysiological results of microelectrode recording (MER).
OBJECTIVE: To determine the correspondence between the preoperative predicted target based on modern 3-T magnetic resonance imaging (MRI) and intraoperative MER results separately on the initial and consecutive second side of surgery.
METHODS: Retrospective cohort study of 86 trajectories of DBS electrodes implanted into the subthalamic nucleus (STN) of patients with Parkinson's disease. The entrance point of the electrode into the STN and the length of the electrode trajectory crossing the STN were determined by intraoperative MER findings and 3 T T2-weighted magnetic resonance images with 1-mm slice thickness.
RESULTS: Average difference between MRI- and MER-based trajectory lengths crossing the STN was 0.28 ± 1.02 mm (95% CI: -0.51 to -0.05 mm). There was a statistically significant difference between the MRI- and MER-based entry points on the initial and second side of surgery (P = .04). Forty-three percent of the patients had a difference of more than ±1 mm of the MRI-based-predicted and the MER-based-determined entry points into the STN with values ranging from -3.0 to + 4.5 mm.
CONCLUSION: STN MRI-based targeting is accurate in the majority of cases on the first and second side of surgery. In 43% of implanted electrodes, we found a relevant deviation of more than 1 mm, supporting the concept of MER as an important tool to guide and optimize targeting and electrode placement.

Entities:  

Mesh:

Year:  2018        PMID: 28973406     DOI: 10.1093/ons/opx175

Source DB:  PubMed          Journal:  Oper Neurosurg (Hagerstown)        ISSN: 2332-4252            Impact factor:   2.703


  6 in total

1.  Optimizing accuracy of freehand cannulation of the ipsilateral ventricle for intracranial pressure monitoring in patients with brain trauma.

Authors:  Zhongyi Sun; Lin Wu; Zhixiong Liu; Weiming Zhong; Zhifeng Kou; Jinfang Liu
Journal:  Quant Imaging Med Surg       Date:  2020-11

2.  Evaluation of preoperative efficacy of levodopa in subthalamic deep brain stimulation.

Authors:  Wen Liu; Xiumin Zhang; Pan Nie; Lidao Chen; Kai Fu; Jibo Zhang; Jincao Chen; Jie Zhang
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

3.  Sleep-wake functions and quality of life in patients with subthalamic deep brain stimulation for Parkinson's disease.

Authors:  Panagiotis Bargiotas; Lukas Eugster; Michael Oberholzer; Ines Debove; M Lenard Lachenmayer; Johannes Mathis; Claudio Pollo; W M Michael Schüpbach; Claudio L Bassetti
Journal:  PLoS One       Date:  2017-12-18       Impact factor: 3.240

4.  Multiple Microelectrode Recordings in STN-DBS Surgery for Parkinson's Disease: A Randomized Study.

Authors:  Silje Bjerknes; Mathias Toft; Ane E Konglund; Uyen Pham; Trine Rygvold Waage; Lena Pedersen; Mona Skjelland; Ira Haraldsen; Stein Andersson; Espen Dietrichs; Inger Marie Skogseid
Journal:  Mov Disord Clin Pract       Date:  2018-05-08

5.  Accuracy of different three-dimensional subcortical human brain atlases for DBS -lead localisation.

Authors:  Andreas Nowacki; T A-K Nguyen; Gerd Tinkhauser; Katrin Petermann; Ines Debove; Roland Wiest; Claudio Pollo
Journal:  Neuroimage Clin       Date:  2018-09-27       Impact factor: 4.881

6.  Directional Local Field Potentials in the Subthalamic Nucleus During Deep Brain Implantation of Parkinson's Disease Patients.

Authors:  T A Khoa Nguyen; Michael Schüpbach; André Mercanzini; Alain Dransart; Claudio Pollo
Journal:  Front Hum Neurosci       Date:  2020-09-30       Impact factor: 3.169

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.